Candriam S.C.A. Immunovant, Inc. Transaction History

Candriam S.C.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 20, 2021	SELL	$9.4 - $16.85 $1.71 Million - $3.06 Million	-181,749 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$36.36 - $52.71 $1.39 Million - $2.02 Million	-38,251 Reduced 17.39%	181,749 $8.4 Million
Q3 2020 Oct 19, 2020	BUY	$22.61 - $38.9 $1.81 Million - $3.11 Million	80,000 Added 57.14%	220,000 $7.74 Million
Q2 2020 Jul 23, 2020	BUY	$13.87 - $28.44 $1.94 Million - $3.98 Million	140,000 New	140,000 $3.41 Million

209

66.6M

2.11M

451K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.